Compare ResMed Inc. (RMD) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs 22nd Century Group Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while 22nd Century Group Inc trades at $2.17 (market cap $1.62M). The key difference: ResMed Inc. is far larger — about 19685.2× 22nd Century Group Inc's market cap, and ResMed Inc. pays a 1.19% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| RMD | XXII | |
|---|---|---|
Market Cap | $31.89B | $1.62M |
Sector | Health | Technology |
52-Week High | $283.28 | $594.00 |
52-Week Low | $182.82 | $2.13 |
Enterprise Value | $31.24B | -$2.69M |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
XXII trades at $2.29, down 4.58% today, showing continued bearish momentum with negative technical signals. The company faces severe financial challenges with negative profit margins (-76.01% net income margin) and consecutive earnings misses. Despite analyst optimism (75% buy ratings), fundamental weakness persists with declining revenue and substantial losses. Recent corporate actions include a 20:1 reverse stock split completed June 2026 to maintain listing compliance.
The outlook remains challenging given persistent operational losses and negative cash flow from operations. Investment opportunity exists if the company can capitalize on its claimed $50B market opportunity and improve gross margins. Key risks include continued cash burn, competitive pressures in tobacco alternatives, and execution challenges in commercializing VLN products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
